Generic Medicine Info
Severe bone marrow depression. Severe hepatic (Child-Pugh class C) and renal (CrCl <30 mL/min) impairment, when used in the treatment of sickle-cell disease. Lactation. Concomitant use w/ didanosine and stavudine.
Special Precautions
Patient w/ severe GI intolerance, history of prior cytotoxic or radiation therapy. Renal and hepatic impairment. Childn. Pregnancy. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. Avoid sun exposure. Monitoring Parameters Monitor CBC w/ differential and platelet (once wkly for antineoplastic indication, every 2 wk initially for sickle cell anaemia), hepatic and renal function, LFT, serum uric, cutaneous toxicities and onset of secondary malignancies. Correct anaemia prior and during therapy.
Adverse Reactions
Significant: Bone marrow suppression (e.g leucopenia, thrombocytopenia, anaemia), cutaneous vasculitic toxicities (e.g. vasculitic ulcerations or gangrene), erythrocyte abnormalities (e.g. self-limiting macrocytosis/megaloblastic erythropoiesis), secondary neoplasms, tumour lysis syndrome. Nervous: Peripheral neuropathy, acute delirium, headache, dizziness, disorientation, malaise, asthenia, hallucination, seizure. CV: Peripheral oedema, hypersensitivity angiitis. GI: Acute mucocutaneous toxicity, diarrhoea, gastric distress, nausea, oral mucosa ulcer, anorexia, constipation, GI irritation, mucositis, stomatitis, vomiting. Resp: Diffuse pulmonary infiltrates, dyspnoea, pulmonary fibrosis, asthma. Hepatic: Elevated liver enzyme, hepatic failure. Genitourinary: Dysuria, increased BUN and creatinine, renal tubular disease. Endocrine: Hyperuricaemia. Haematologic: Leukaemia, abnormal erythropoiesis, macrocytosis, reticulocytopenia, cytopenia, myeloproliferative disorder (e.g. polycythemia, secondary leukaemia). Musculoskeletal: Panniculitis, weakness. Dermatologic: Maculopapular rash, skin ulceration, dermatomyositis-like skin changes, facial oedema, rash, pruritus, alopecia, hyperpigmentation, skin and nails atrophy, violet papules, cutaneous leg ulcers and skin carcinoma, eczema, desquamation, peripheral and facial erythema. Others: Fever, chills.
Potentially Fatal: Severe myelosuppression.
Drug Interactions
Increased risk of cutaneous vasculitic ulcerations w/ prior or concomitant use of interferon. Admin of live vaccine may cause severe infection due to the decreased patient's antibody response.
CIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XX05 - hydroxycarbamide ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on hydroxycarbamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in